Seeking Alpha

Astex Pharmaceuticals (ASTX -4.8%) says updated clinical data from a phase 1/2 trial of...

Astex Pharmaceuticals (ASTX -4.8%) says updated clinical data from a phase 1/2 trial of subcutaneous SGI-110 in patients with relapsed/refractory acute myelogenous leukemia has been chosen for oral presentation on September 28 at the European Cancer Congress. (Previous: ASTX says SGI-110 produces overall response rate of 40%)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs